DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Blood Plasma Market: Industry Analysis & Outlook (2017-2021)" report to their offering.
"Global Blood Plasma Market: Industry Analysis & Outlook (2017-2021)" provides an extensive research and detailed analysis of the market performance at present and future outlook of the market.
North America's blood plasma market accounts for the largest market share because of its strong market dynamics and greater scope of innovation in the region. The global blood plasma market growth will be driven by increased diagnosis rate, high plasma demand especially for albumin from the emerging economies, increase in number of patients suffering from CIDP and rising plasma donations.
The major trends of the market include innovation in therapeutics via existing & new proteins, growing AATD market potential and escalating fractionation capacity. However, the market will be hindered by high cost of treatment and lengthy process to open plasma centers and high R&D costs. Also, the competition of the market will be largely dominated by top three firms, thereby creating oligopolistic situation globally.
It also covers global as well as regional aspect of the market. The report profiles the top notch players of the market including Shire Plc., CSL Limited, Grifols, S.A., and Octapharma Inc.
Trends & Developments
- Increasing Fractionation Capacity
- Growing AATD Market Potential
- Innovation in Therapeutics Via Existing and New Proteins
- Increased Diagnosis of Disease Treated by Immunoglobulin
- Increasing Plasma Collection
- Growing Blood Plasma Market in Emerging Economies
- Popularity of Albumin in Asian Countries
- Increasing Healthcare Expenditure
- Escalating Ageing Population
Challenges & Issues
- High Cost of Treatment
- Unclear & Lengthy Process to Open Plasma Centre
- High R&D Costs
Key Topics Covered:
1. Market Overview
2. Global Market Analysis
3. Regional Analysis
4. Market Dynamics
5. Competitive Landscape
6. Company Profiles
- CSL Limited
- Grifols, S.A.
- Octapharma, Inc.
- Shire Plc.
For more information about this report visit http://www.researchandmarkets.com/research/mjm28q/global_blood